IVVD News & Events

Invivyd announced the appointment of Michael Mina, M.D., Ph.D., as Chief Medical Officer. Mina is a former assistant professor at the Harvard T.H. Chan School of Public Health, Harvard Medical School and Brigham and Women's Hospital, and he has served as chief science or chief medical officer at several diagnostics and digital health companies.

Cash and cash equivalents were $226.7 million as of December 31, 2025. In the second half of 2025, Invivyd secured over $200 million of capital. Invivyd's current cash and cash equivalents are anticipated to be sufficient to support the DECLARATION pivotal clinical trial, commercial preparedness for the potential launch of VYD2311, continued research and development related to its pipeline programs such as RSV and measles, continued advancement of the SPEAR Study Group efforts related to assessing the effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and for working capital and other general corporate purposes.

Reports revenue $53.4M, consensus $51.72M. "With potential commercialization of VYD2311 on the horizon, we are encouraged by continued commercial execution and appeal for monoclonal antibody prophylaxis demonstrated by revenue of PEMGARDA more than doubling year over year, while operating expenses were reduced by nearly half," noted Bill Duke, Chief Financial Officer of Invivyd. "While we are pleased with Invivyd's ability to exhibit financial discipline, we are most excited about the positive momentum behind VYD2311 and that our recent capital raises enable us to invest in the ongoing DECLARATION pivotal clinical trial and potential commercialization, if approved, in addition to our other pipeline programs."

Invivyd announced a peer-reviewed publication by Invivyd that uses data from the recent CANOPY clinical trial of Invivyd's monoclonal antibody pemivibart to predict clinical protection levels from COVID purely from laboratory-determined serum monoclonal antibody activity levels, irrespective of virus variation. This newly published analysis builds on similar, earlier peer-reviewed analyses demonstrating similar findings from pre-Omicron virus variants with a prior Invivyd antibody. "Our perspective at Invivyd from the beginning of the COVID pandemic through today is clear: we believe that once the safety of an Invivyd COVID monoclonal antibody that targets a stable epitope on the virus has been established, one can reliably estimate its ability to prevent COVID disease directly from its laboratory-assessed antiviral activity," said Robert Allen, Ph.D., Chief Scientific Officer at Invivyd. "As we continue to develop this field, our hope is that healthcare professionals, policymakers, and regulators will recognize the demonstrated consistent responsiveness of SARS-CoV-2 to our highly active monoclonal antibodies, irrespective of virus variation, which may enhance the development and use of new monoclonal antibody options for patients in need, if approved."